Outlook Therapeutics, Inc. (OTLK)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Outlook Therapeutics, Inc. (OTLK)
Company Performance

Current Price

as of Oct 16, 2024

$5.19

P/E Ratio

N/A

Market Cap

$122.77M

Description

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Metrics

Overview

  • HQIselin, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerOTLK
  • Price$5.19+1.37%

Trading Information

  • Market Cap$122.77M
  • Float64.40%
  • Average Daily Volume (1m)254,549
  • Average Daily Volume (3m)216,865
  • EPS-$7.95

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income$44.41M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$19.53M
  • EV$188.72M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/BN/A
Documents
SEC Filings
8-K (2024-08-14)
8-K (2024-07-08)
8-K (2024-05-28)
8-K (2024-05-15)
8-K (2024-05-13)
8-K (2024-05-01)
8-K (2024-04-15)
8-K (2024-04-12)
8-K (2024-04-02)
8-K (2024-03-26)
8-K (2024-03-18)
8-K (2024-03-07)
8-K (2024-02-14)
8-K (2024-01-24)
8-K (2023-12-22)
8-K (2023-12-06)
8-K (2023-11-02)
8-K (2023-10-20)
8-K (2023-08-30)
8-K (2023-08-14)
8-K (2023-05-16)
8-K (2023-05-15)
8-K (2023-03-30)
8-K (2023-02-14)
10-Q (2024-08-14)
10-Q (2024-05-15)
10-Q (2024-02-14)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-Q (2023-02-14)
10-K (2023-12-22)
Earnings Calls
Earnings Report 2024Q3
Earnings Report 2024Q2
Factset
Factset Business Description
Factset Street Account
Outlook Therapeutics upgraded to buy from neutral at HC Wainwright ($0.34, 0.00) (2023-11-03T10:13:31Z)
Outlook Therapeutics submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010 ($0.38, 0.00) (2023-12-19T13:12:33Z)
Outlook Therapeutics provides update on Type A meetings with FDA ($0.63, 0.00) (2023-11-02T12:12:09Z)
Outlook Therapeutics announces receipt of Type A meeting minutes and reiterates regulatory path forward for ONS-5010 ($0.46, 0.00) (2023-11-27T13:07:41Z)